FTRE - Fortrea Holdings Inc. News

Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $29

Truist Securities analyst Jailendra Singh maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and

Barclays Maintains Overweight on Fortrea Holdings, Raises Price Target to $26

Barclays analyst Luke Sergott maintains Fortrea Holdings (NASDAQ:FTRE) with a Overweight and rais

Evercore ISI Group Maintains Outperform on Fortrea Holdings, Raises Price Target to $28

Evercore ISI Group analyst Elizabeth Anderson maintains Fortrea Holdings (NASDAQ:FTRE) with a Out

marketbeat.com

What Fortrea (FTRE) Said on Its Q3 Earnings Call

Fortrea NASDAQ: FTRE reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year ea

seekingalpha.com

Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript

Fortrea Holdings Q3 2026 Earnings Call Transcript

Fortrea Holdings (NASDAQ:FTRE) reported third-quarter financial results on Thursday. The transcript

zacks.com

Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimates

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.28 per share, beating the Zacks

Fortrea Holdings Raises FY2026 Sales Guidance from $2.620B-$2.690B to $2.665B-$2.690B vs $2.663B Est

Fortrea Holdings (NASDAQ:FTRE) raises FY2026 sales outlook from $2.620 billion-$2.690 billion to $2.

Fortrea Holdings Q3 Adj. EPS $0.28 Beats $0.22 Estimate, Sales $691.500M Beat $669.951M Estimate

Fortrea Holdings (NASDAQ:FTRE) reported quarterly earnings of $0.28 per share which beat the analyst

Fortrea Reports Third Quarter 2026 Results

Sustained commercial momentum, continued margin improvement, and targeted investments strengthen gro

Fortrea to Participate in Jefferies Global Healthcare Conference

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract re

Fortrea And Omico Collaborate To Accelerate Precision Oncology Research By Helping Connect Cancer Pa

HighlightsCollaboration aims to accelerate precision oncology research in AustraliaCombines Fortrea’

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies

zacks.com

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a

9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

UBS Maintains Neutral on Fortrea Holdings, Raises Price Target to $24

UBS analyst Kevin Caliendo maintains Fortrea Holdings (NASDAQ:FTRE) with a Neutral and raises the

Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials

Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinica

seekingalpha.com

3 Top Small-Cap Stocks With Market-Beating Momentum

Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, bu

Deutsche Bank Upgrades Fortrea Holdings to Buy, Raises Price Target to $25

Deutsche Bank analyst Justin Bowers upgrades Fortrea Holdings (NASDAQ:FTRE) from Hold to Buy and

MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head Contrast

Fortrea (NASDAQ: FTRE - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both smal

Ausbil Investment Management Ltd Decreases Stake in Fortrea Holdings Inc. $FTRE

Ausbil Investment Management Ltd trimmed its position in Fortrea Holdings Inc. (NASDAQ: FTRE) by 25.

Fortrea (NASDAQ:FTRE) Reaches New 52-Week High – What’s Next?

Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) reached a new 52-week high during trading on

Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big S

U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo

Barclays Upgrades Fortrea Holdings to Overweight, Raises Price Target to $23

Barclays analyst Luke Sergott upgrades Fortrea Holdings (NASDAQ:FTRE) from Equal-Weight to Overwe

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading gl

Fortrea Holdings Inc. (NASDAQ:FTRE) Stock Rated “Hold” by Sell-Side Brokerages

Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) has received a consensus rating of "Hold" fro

UBS Initiates Coverage On Fortrea Holdings with Neutral Rating, Announces Price Target of $22

UBS analyst Kevin Caliendo initiates coverage on Fortrea Holdings (NASDAQ:FTRE) with a Neutral ra

Financial Survey: Fortrea (NASDAQ:FTRE) vs. Bullfrog AI (NASDAQ:BFRG)

Fortrea (NASDAQ: FTRE - Get Free Report) and Bullfrog AI (NASDAQ: BFRG - Get Free Report) are both s

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading g

Fortrea to Participate in September Investor Conferences

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract r

Fortrea Reinstates Jason Knoblauch As CFO

David Smith, a current director on the Board, had acted as Interim Chief Financial Officer and princ

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea acquires Worldwide Clinical Trials' Early Phase division for $45 million in cash to expa

Fortrea to Acquire the Early Phase Services business from Worldwide in an all-cash transaction value

Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical developm

seekingalpha.com

Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost

TD Cowen Maintains Buy on Fortrea Holdings, Raises Price Target to $23

TD Cowen analyst Charles Rhyee maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and raises the

Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $22

Citigroup analyst Brendan Digan maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and raises th

Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $26

Truist Securities analyst Jailendra Singh maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and

Evercore ISI Group Maintains Outperform on Fortrea Holdings, Raises Price Target to $25

Evercore ISI Group analyst Elizabeth Anderson maintains Fortrea Holdings (NASDAQ:FTRE) with a Out

Barclays Maintains Equal-Weight on Fortrea Holdings, Raises Price Target to $22

Barclays analyst Luke Sergott maintains Fortrea Holdings (NASDAQ:FTRE) with a Equal-Weight and ra

Fortrea Holdings Q2 Adj. EPS $0.23 Beats $0.18 Estimate, Sales $678.200M Beat $647.465M Estimate

Fortrea Holdings (NASDAQ:FTRE) reported quarterly earnings of $0.23 per share which beat the analyst

Fortrea Holdings Raises FY2026 Sales Guidance from $2.550B-$2.650B to $2.620B-$2.690B vs $2.607B Est

Fortrea Holdings (NASDAQ:FTRE) raises FY2026 sales outlook from $2.550 billion-$2.650 billion to $2.

Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $16

Mizuho analyst Ann Hynes maintains Fortrea Holdings (NASDAQ:FTRE) with a Neutral and raises the p

Fortrea Reiterates FY26 Guidance, Targeting Revenues In Range Of $2.550B-$2.650B Vs $2.594B Est., An

2026 Financial GuidanceThe Company reiterates its guidance for the full year 2026, targeting revenue

Fortrea Appoints Jason Knoblauch As CFO, Effective July 6, Succeeding Jill Mcconnell

Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO)

Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Barclays Maintains Equal-Weight on Fortrea Holdings, Raises Price Target to $18

Barclays analyst Luke Sergott maintains Fortrea Holdings (NASDAQ:FTRE) with a Equal-Weight and ra

Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $13

Mizuho analyst Ann Hynes maintains Fortrea Holdings (NASDAQ:FTRE) with a Neutral and raises the p